AlphAIalphai — Financial news for AI agents
StockHealthcare · Biotechnology

$CRBU

Caribou Biosciences, Inc.

Price · $CRBUvia TradingView
AI sentiment · 7d0 articles

No enriched coverage for $CRBU in the last 7 days.

Insider · 30dFeed →

No SEC Form 4 filings for $CRBU in the last 30 days.

Top stories · $CRBUMore →
MAY 14·Traders UnionMed

Caribou Biosciences attends BioConnect Investor Conference in New York next week

Caribou Biosciences announced its participation in the 4th Annual BioConnect Investor Conference hosted by H.C. Wainwright in New York City, where it will showcase its CRISPR-based cell therapies to investors and industry leaders. This appearance is part of the company's ongoing active conference schedule, which recently included CEO Rachel Haurwitz speaking at the BofA Securities Health Care Conference and a Bank of America webcast. The company continues to actively engage with investors and stakeholders to highlight its advancements in biotechnology.

MAY 14·AD HOC NEWS

Caribou Biosciences stock (US1420381089): Q1 earnings beat and 4.4% surge

Caribou Biosciences (CRBU) reported stronger-than-expected Q1 2026 earnings, with EPS of -$0.26 beating estimates by $0.07 and revenue of $2.4 million exceeding forecasts. Following this news and the announcement of their participation in a H.C. Wainwright conference, the company's stock surged 4.43% to $2.12 on May 13. Caribou Biosciences develops allogeneic CAR-T cell therapies using its proprietary CRISPR-based chRDNA platform for cancer and autoimmune diseases, with lead candidates like CB-010 and CB-011 (which received FDA RMAT designation) driving pipeline progress.

MAY 14·Simply Wall Street

May 2026's Promising Penny Stocks

This article identifies promising "penny stocks" for May 2026, focusing on companies with strong financials and growth potential in a flat market. It highlights three specific companies: Whitehawk Therapeutics (WHWK), Caribou Biosciences (CRBU), and Zion Oil & Gas (ZNOG), detailing their current financial status, operations, and recent developments. The article emphasizes that while these companies are pre-revenue or currently unprofitable, they show potential due to factors like significant investor interest, advancing clinical trials, or strong balance sheets despite other challenges.

News on $CRBU

All news →